Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/12821
Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers
Identifiers
ISSN: 1471-2377
WOS ID: 000321782000001
Scopus EID: 2-s2.0-84880023437
PMID: 23845043
Embase PUI: L52683151
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordAuthor
Munoz, Delicias; Escartin, Antonio; Dapena, Dolores; Coret, Francisco; Fernandez-Uria, Dionisio; Perez, Domingo; Casanova, Bonaventura; Guijarro-Castro, Cristina; Munteis, Elvira; del-Campo Amigo, Mara; Pego, Robustiano; Calles, Carmen; Garcia-Rey, Cesar; Monsalve, Nuria; Sanchez-Matienzo, DavidPublication date
2013-07-11Document type
research articleCitation
Muñoz D, Escartin A, Dapena D, Coret F, Fernandez-Uria D, Perez D, et al. Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers. BMC Neurol. 2013 Jul 11;13:82.Abstract
Background: This study aimed to correlate body mass index or biomarkers with the frequency of common adverse events (AEs) with subcutaneous IFN beta-1a during treatment titration in patients with relapsing-remitting multiple sclerosis previously naive to IFN beta. Methods: Eighty-four patients (66.3% females) were followed up during 8 weeks, 25.3% were overweight and 14.5% were obese. Results: Biomarkers steadily increased during all study period by 45.3% for beta 2-microglobulin, 262.8% for olygoadenylate synthetase-1, and 92.8% for neopterin. Overall AE reporting did not vary with the dose or treatment duration. Conclusions: BMI was not predictive of increased risk for AEs. Biomarkers did not discriminate on the frequency of any AE either.
Publisher version
https://dx.doi.org/10.1186/1471-2377-13-82Keywords
Interferon beta-1aBody mass index
Biomarkers
beta 2-microglobulin
OAS
Neopterin
Adverse events
MeSH
beta 2-MicroglobulinKaplan-Meier Estimate
Follow-Up Studies
Humans
Immunologic Factors
Male
Predictive Value of Tests
Female
Multiple Sclerosis, Chronic Progressive
Treatment Outcome
Body Mass Index
Interferon-beta
Neopterin
Retrospective Studies
DeCS
Índice de Masa CorporalNeopterin
Resultado del Tratamiento
Interferón beta
Femenino
Factores Inmunológicos
Masculino
Estudios de Seguimiento
Humanos
Valor Predictivo de las Pruebas
Estimación de Kaplan-Meier
Microglobulina beta-2
Estudios Retrospectivos
Esclerosis Múltiple Crónica Progresiva